A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
Status:
Completed
Trial end date:
2017-06-20
Target enrollment:
Participant gender:
Summary
The primary aim of the study is to determine the efficacy of adjunctive valacyclovir, in
comparison to placebo, to improve visual (Brief Visuospatial Memory Test) and working
(composite score of the Spatial Span and Letter Number Span tests) memory in individuals who
are HSV-1 positive and early in the course of schizophrenia.
We hypothesize that individuals who are HSV-1 positive, but not those who are HSV-1 negative,
will demonstrate significant valacyclovir efficacy for visual and working memory.
Phase:
Phase 2
Details
Lead Sponsor:
Indiana University
Collaborators:
Centers for Behavioral Health, LLC Clinical Innovations Innovative Clinical Research, Inc. Laureate Institute for Brain Research, Inc. Sheppard Pratt Health System Stanley Medical Research Institute University of California Riverside at C.I. Trials, Inc.-Inland Empire University of California, Los Angeles University of Kansas Medical Center University of Maryland University of Maryland, College Park Yale University